SCT200 is a fully humanized IgG1 monoclonal antibody targeting EGFR, with a Kd value of 0.08 nM. It can eliminate tumor cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through its Fc fragment. SCT200 is utilized in research on refractory RAS and BRAF wild-type metastatic colorectal cancer.
Target-Kategorie:
EGFR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
